Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval

[cafead]

via Less than a month after submitting its Investigational New Drug (IND) application, Anixa Biosciences has run into a snag with the U.S. Food and Drug Administration (FDA). The government agency is asking for more information before approving a clinical study on the company’s Chimeric Antigen Receptor-T cell therapy (CAR-T).

article source